Results 111 to 120 of about 1,181,836 (211)

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial

Journal of Internal Medicine, 2019
The 52‐week, randomized, double‐blind, noninferiority, government‐funded NOR‐SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT‐P13 was not inferior to continued treatment with infliximab originator.
G. Goll, K. Jørgensen, J. Sexton, Inge Christoffer Olsen, N. Bolstad, E. Haavardsholm, K. Lundin, K. Tveit, M. Lorentzen, I. Berset, B. Fevang, S. Kalstad, K. Ryggen, D. Warren, R. Klaasen, Ø. Asak, S. Baigh, I. Blomgren, Ø. Brenna, T. Bruun, K. Dvergsnes, S. Frigstad, I. M. Hansen, I. S. H. Hatten, G. Huppertz-Hauss, M. Henriksen, S. Høie, J. Krogh, I. P. Midtgard, P. Mielnik, B. Moum, G. Noraberg, A. Poyan, U. Prestegård, H. U. Rashid, E. K. Strand, K. Skjetne, K. A. Seeberg, R. Torp, C. Ystrøm, C. Vold, C. Zettel, K. Waksvik, B. Gulbrandsen, J. Hagfors, C. Mørk, J. Jahnsen, T. Kvien   +47 more
semanticscholar   +1 more source

Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis [PDF]

Scandinavian Journal of Gastroenterology, 2016
The infliximab biosimilar CT-P13 (Remsima(®), Inflectra(®)) was approved in Europe for the treatment of inflammatory bowel disease (IBD) based on extrapolation of data from patients with rheumatic disease. Because there are limited published reports on clinical outcomes for IBD patients treated with CT-P13, we monitored responses to induction treatment
Keil, Radan, Wasserbauer, Martin, Zádorová, Zdena, Hajer, Jan, Drastich, Pavel, Wohl, Pavel, Beneš, Marek, Bojková, Martina, Svoboda, Pavel, Konečný, Michal, Falt, Přemysl, Vaňásek, Tomáš, Pešta, Martin, Pešek, František, Bouchner, Luděk, Koželuhová, Jana, Novotný, Aleš, Bartůsková, Lucie, Špičák, Julius   +18 more
openaire   +2 more sources

Integrative genomic and functional analyses reveal NINL as a modulator of tau aggregation

Alzheimer's &Dementia, Volume 22, Issue 4, April 2026.
Abstract INTRODUCTION Proteostasis dysfunction is a hallmark of frontotemporal dementia (FTD) and Alzheimer's disease (AD), yet the genetic and molecular pathways that disrupt protein homeostasis remain poorly understood. METHODS We integrated human genetics, transcriptomics, and functional studies to identify proteostasis network components involved ...
Samantha K. Swift, Guangming Huang, J. Nicholas Cochran, Ricardo D'Oliveira Albanus, Miguel A. Minaya, Patricia A. Castruita, Rui Zhang, Katherine J. Miller, Emma Starr, Grant Galasso, Jacob A. Marsh, Aimee W. Kao, Oscar Harari, Jennifer S. Yokoyama, Celeste M. Karch   +14 more
wiley   +1 more source

Chronic Myeloid Leukemia Presenting With T‐Lymphoid Blast Crisis in a Young Female With Marked Hyperleukocytosis: A Case Report

eJHaem, Volume 7, Issue 2, April 2026.
Abstract Background Chronic myeloid leukemia (CML) presenting in blast crisis (BC) is uncommon in the era of tyrosine kinase inhibitor (TKI) treatment, and T‐lymphoblastic BC is exceptionally rare. We report a case of T‐lymphoid BC presenting with extreme hyperleukocytosis.
E. Somasundaram, R. P. Hasserjian, B. J. Aubrey, A. T. Fathi, H. Hock   +4 more
wiley   +1 more source

The Portuguese Society of Rheumatology position paper on the use of biosimilars [PDF]

, 2014
Biotechnological drugs have become a fundamental resource for the treatment of rheumatic patients. Patent expiry of some of these drugs created the opportunity for biopharmaceutical manufacturers to develop biosimilar drugs intended to be as efficacious ...
Aguiar, R, Ambrósio, C, André, R, Araújo, F, Barcelos, F, Bernardes, M, Bogas, M, Canhão, H, Castelão, W, Coelho, PC, Cordeiro, I, Costa, L, Cunha, I, Duarte, C, Faustino, A, Fernandes, S, Fonseca, JE, Garcês, S, Gonçalves, J, Las, V, Leitão, R, Malcata, A, Maurício, L, Meirinhos, T, Melo-Gomes, JA, Miguel, C, Miranda, LC, Monteiro, P, Neto, A, Pereira da Silva, JA, Pimenta, S, Pimentel-Santos, FM, Pimentão, JB, Ramiro, Sofia, Ramos, JC, Roxo, Ana, Santos, H, Sepriano, A, Silva, C, Silva, M, Tavares, V, Teixeira, F   +41 more
core  

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation [PDF]

, 2017
Background: Psoriasis is a chronic inflammatory disease that predominantly affects the skin. Adalimumab (HUMIRA®, AbbVie, Maidenhead, UK), etanercept (Enbrel®, Pfizer, New York, NY, USA) and ustekinumab (STELARA®, Janssen Biotech, Inc., Titusville, NJ ...
AbbVie, Ali, All Wales Medicines Strategy Group, All Wales Therapeutics and Toxicology Centre, Altmeyer, Amgen Inc, Amgen Inc, Amgen Inc, Amgen Inc, Amornpinyokeit, Asahina, Balzola, Barker, Basko-Plluska, Basra, Benoit, Berth-Jones, Bigby, Bissonnette, Bonafede, Brunasso, Brănişteanu, Burden-Teh, Burden-Teh, Burden-Teh, Burmester, Burmester, Centre for Reviews and Dissemination, Chaudhari, Chen, Chingcuanco, Chiu, Christiansen, Christophers, Cooper, Corbett, da Silva, Dakin, de Jager, De Jager, de Jager, Department of Health, Dias, Dias, Dias, Dias, DiMarco, Dixon, Dolan, Driessen, Eissing, Elder, Elewski, Esposito, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, EuroQol Research Foundation, Faerber, Fallah Arani, Famenini, Farhi, Feldman, Flytström, Fonia, Garber, Geiger, Gisondi, Gniadecki, Gniadecki, Gordon, Gordon, Gottlieb, Gottlieb, Greater Medicines Management Group, Griffiths, Guenther, Heydendael, Heydendael, Higgins, Higgins, Ho, Holme, Howe, Ibfelt, Ibrahim, Igarashi, Italian Multicenter Study Group on Cyclosporin in Psoriasis, Janagond, Jankovic, Janssen Biotech, Inc, Janssen Research & Development, LLC, Janssen Research & Development, LLC, Janssen Research & Development, LLC, Janssen-Cilag International, Joint Formulary Committee, Khan, Kim, Kim, Kimball, Klufas, Koo, Kragballe, Krueger, Krueger, Kurd, Laburte, Landells, Landells, Landells, Langley, Langley, Langley, Langley, Lara-Corrales, Lebwohl, Lebwohl, Lefebvre, Lefebvre, Leman, Leonardi, Leonardi, Levy, Lewis-Jones, Lu, Lynde, López-Ferrer, Mahé, Meffert, Melis, Menter, Menter, Menter, MIMS, Moher, National Horizon Scanning Centre, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, NIHR Horizon Scanning Centre, NIHR Horizon Scanning Centre, Norman, Novartis Pharmaceuticals, Novartis Pharmaceuticals, Office for National Statistics, Oostveen, Paller, Paller, Paller, Paller, Paller, Paller, Paller, Paller, Paller, Papp, Papp, Papp, Papp, Papp, Papp, Papp, Papp, Papp, Parisi, Park, Paul, Pereira, Pfizer, Pfizer, Phillipp, Puig, Ranjan, Reich, Reich, Rencz, Revicki, Richardson, Rodgers, Romero-Maté, Royal College of Paediatrics and Child Health, Ruano, Ruzicka, Ryan, Salek, Sanclemente, Saurat, Schabert, Seminara, Seyger, Shah, Siegfried, Siegfried, Signorovitch, Smith, Soliman, Strand, Strohal, Strohal, Sutton, Takashima, Tanew, Tarp, Torii, Tsai, Umezawa, Upton, US Food and Drug Administration, van de Kerkhof, van Reenen, Varni, Varni, Varni, Vencovsky, Vickers, Warren, Warren, Woods, Woolacott, Wu, Wyeth, Yang, Young, Zachariae, Zhu   +239 more
core   +3 more sources

Impact of Immunogenicity on Clinical Outcomes in Patients With Moderate‐to‐Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY Trials

United European Gastroenterology Journal, Volume 14, Issue 3, April 2026.
ABSTRACT Background and Aims LIBERTY‐CD and LIBERTY‐UC demonstrated superior efficacy of subcutaneous infliximab (IFX SC) to placebo in patients with Crohn's disease (CD) or ulcerative colitis (UC). Here, we investigated the impact of anti‐drug antibodies (ADAs) on clinical outcomes.
Jean‐Frédéric Colombel, Silvio Danese, Stefan Schreiber, Bruce E. Sands, Andres J. Yarur, Aram Kang, Dong‐Hyeon Kim, Young Nam Lee, Stephen B. Hanauer   +8 more
wiley   +1 more source

PGI12 Mean Annual Cost Of Patients Hospitalized For Chronic Hepatitis C In France: The Hepc-Lone Study [PDF]

, 2014
Las relaciones laborales marítimas se singularizan por caracteres que han propiciado la necesidad de formular instrumentos que tutelen los derechos de la gente de mar. Entre las singularidades más destacadas está el centro de trabajo: el buque.
Abergel, A., Rotily, M., Gaudin, A.F., De, Léotoing L., Vainchtock, A., Akremi, R., Branchoux, S.   +6 more
core   +3 more sources

Combined Transcriptomic and Proteomic Forecast Analyses for Potential Biomarkers of Smoking‐Induced Benign and Malignant Transformation of Vocal Fold Lesions

World Journal of Otorhinolaryngology - Head and Neck Surgery, Volume 12, Issue 2, Page 168-176, April 2026.
ABSTRACT Objective Laryngeal dysplasia and Reinke's edema (RE) are common vocal fold lesions associated with smoking. While the former is cancer prone, most cases of the latter do not undergo malignant transformation. Therefore, we proposed identifying biomarkers of smoking‐induced benign‐malignant transformation of vocal fold lesions.
Yun‐Yi Liu, Pei‐Yun Zhuang
wiley   +1 more source

ARE WE READY FOR MULTIPLE SWITCHES BETWEEN REFERENCE PRODUCTS AND BIOSIMILARS? [PDF]

Arquivos de Gastroenterologia
Inflammatory bowel diseases (IBD) currently impose an immense social and economic burden on society in terms of both direct and indirect healthcare costs. Their incurable and progressive nature results in an unavoidable lifetime expense. The introduction
Fabio Vieira TEIXEIRA, Laurent PEYRIN-BIROULET, Silvio DANESE   +2 more
doaj   +1 more source